Comparison · NCT03805100-sae
Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Xlucane (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): serious adverse events. Trial comparisons, record NCT03805100-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03805100-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.113 | 0.0816 | 0.154 | wilson | |
| Risk in group 2 | 0.121 | 0.0881 | 0.163 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00768 | -0.0605 | 0.0451 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.936 | 0.599 | 1.46 | log | |
| Odds ratio, group 1 over group 2 | 0.928 | 0.56 | 1.54 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Xlucane (Proposed Ranibizumab Biosimilar) than on Lucentis (Ranibizumab) | 130 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Xlucane (Proposed Ranibizumab Biosimilar) | Xlucane (proposed ranibizumab biosimilar) in the study eye monthly for 52 weeks by intravitreal injection. | 33 | 292 | EG000 |
| Group 2 | Lucentis (Ranibizumab) | Lucentis (ranibizumab) in the study eye monthly for 52 weeks by intravitreal injection | 35 | 290 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time the participant signed the written informed consent to 28 days [± 5 days] of receiving last dose of study drug, up to 53 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
- NCT number
- NCT03805100
- Phases
- PHASE3
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Lead sponsor
- Xbrane Biopharma AB
- Results first posted
- 2023-11-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03805100?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03805100-sae